Healthcare CDMO Market Report Scope & Overview:

The Healthcare CDMO Market was valued at USD 312.70 Billion in 2025 and is expected to reach USD 814.75 Billion by 2035, growing at a CAGR of 10.05% from 2026-2035.

The Healthcare CDMO Market is driven by the rise in demand for outsourcing, increasing pipelines in the pharmaceutical and biotechnology industry, and increased focus on cost efficiency and fast clinical process. Increasing focus of biopharmaceutical companies to invest money in research and development while outsourcing the specialized manufacturing of biologics, cell and gene therapies, antibody drug conjugate, and mRNA technologies which require advanced technology and knowledge of regulation is driving the market. Key players are adopting single-use and continuous manufacturing technologies, integrating artificial intelligence in technology transfer processes, and developing late-stage development capabilities. Geographical diversity in GMP capacity, particularly in Asia Pacific, is providing cost-effective supply solutions. Competition is also moving from price bidding to capability.

In December 2024, Novo Holdings completed its approximately USD 16.5 billion acquisition of Catalent, strengthening its position in integrated biologics manufacturing. Novo Nordisk separately acquired three Catalent fill-finish sites in the United States, Italy, and Belgium, adding sterile injectable capacity and highlighting accelerating consolidation across the global CDMO sector.

Healthcare CDMO Market Trends

• Sponsors are increasingly engaging CDMOs earlier in development, blurring traditional boundaries between contract development and contract manufacturing services.

• Integrated platforms combining biologic expression, payload synthesis, conjugation, and aseptic fill-finish under a single quality system are shortening antibody-drug conjugate development timelines.

• Artificial intelligence-driven process optimization and digital twins are cutting technology-transfer scale-up cycles by as much as 30%.

• Capacity expansion for high-potency APIs, viral vector suites, and sterile injectables remains a top investment priority amid persistent multi-year capacity constraints.

• Government incentives across China, Singapore, and South Korea are lowering capital hurdles for new GMP capacity in Asia-Pacific.

• M&A activity is accelerating industry consolidation as established players and investors compete for integrated, large-scale biologics manufacturing capability.

U.S. Healthcare CDMO Market Outlook

The U.S. Healthcare CDMO Market was valued at USD 111.90 Billion in 2025 and is expected to reach USD 270.34 Billion by 2035, growing at a CAGR of 9.22% from 2026-2035.

The U.S. Healthcare CDMO market continues to grow on the back of robust outsourcing trends among pharmaceutical and biotech organizations, especially when it comes to biological drugs, cell and gene therapy, and sterile injectable drug formulations. The market is well versed in FDA regulations and cold chain logistics; thus, contributing to a significant competitive advantage that is enjoyed by the country in the outsourced manufacturing space. The abundance of pharmaceutical company headquarters, biotech firms, research organizations, and innovation centers in the United States makes the sponsors prefer in-country manufacturing for both developmental and commercial operations. While labor and utilities costs increase, the demand will continue to be stimulated by the quality, regulatory reliability, and supply assurance.

In March 2025, Syngene International announced its first U.S. facility in Maryland, a 17,000-square-foot cGMP-compliant site expanding CDMO capabilities and client proximity. The facility complements its Indian biologics operations, where single-use bioreactor capacity is increasing from 20,000 to 50,000 liters, supporting integrated development and commercial manufacturing services.

Healthcare CDMO Market Segment Analysis

• By Product Type, the Small Molecule segment dominated the Healthcare CDMO Market with approximately 45.90% share in 2025, while the Large Molecule segment is the fastest growing with a CAGR of approximately 12.50%.

• By Service Type, the Contract Manufacturing segment dominated the Healthcare CDMO Market with approximately 65.10% share in 2025, while the Contract Development segment is the fastest growing with a CAGR of approximately 10.80%.

• By Development Phase, the Commercial segment dominated the Healthcare CDMO Market with approximately 39.35% share in 2025, while the Phase I segment is the fastest growing with a CAGR of approximately 10.78%.

• By Therapeutic Area, the Oncology segment dominated the Healthcare CDMO Market with approximately 31.80% share in 2025, while the Neurology segment is the fastest growing with a CAGR of approximately 11.50%.

• By End-User, the Big Pharmaceutical Companies segment dominated the Healthcare CDMO Market with approximately 53.40% share in 2025, while the Emerging & Virtual Biotech Firms segment is the fastest growing with a CAGR of approximately 11.35%.

By Product Type, Small Molecule Dominates and Large Molecule Grows Fastest

Small Molecule is projected to account for the largest share of the Healthcare CDMO Market in 2025, owing to the presence of a broad range of approved small molecule drugs, generics, specialty drugs, and high potency APIs. The already existing small molecule manufacturing infrastructure, which enables CDMOs to undertake projects at different stages of drug development, from discovery to clinical trials and commercialization, drives pharmaceutical companies to outsource such services to reduce costs. The demand is particularly high in oncology, cardiovascular, metabolic, and rare disease drug development programs, which require sophisticated chemistry and high potency APIs. All these trends make the segment one of the key segments of healthcare outsourcing market.

Large Molecule is expected to witness the fastest growth among all segments of the Healthcare CDMO Product Type. The growing pipeline of biologics, antibodies, recombinant proteins, and other complex molecules is driving the demand for outsourced development, production, and clinical and commercial manufacturing services among drug developers. These services are highly specialized and can be provided only by means of specialized infrastructure. The emerging trend of personalized medicine and targeted therapies, as well as investments into biologics manufacturing capabilities, encourage the pharma and biotech companies to enter long-term strategic partnerships.

By Service Type, Contract Manufacturing Dominates and Contract Development Grows Fastest

Contract Manufacturing In 2025, will top the Healthcare CDMO industry, due to increasing outsourcing by the pharmaceutical companies. The process gives the sponsors an opportunity to access established manufacturing platforms, technical expertise, scaleable manufacturing capacities, and compliant manufacturing facilities without being tied to any capital investment. The rise in the market will be fueled by the increasing demand in generic drugs manufacturing, complexities involved in pharmaceutical manufacturing and flexible manufacturing capacities. CDMOs are increasingly expanding their integrated manufacturing platforms for API manufacture, finished dosage forms, biologics and others products to cater for their sponsors throughout the value chain.

Contract Development Expected to experience the highest growth in the forecast period is contract development due to increasing demand by pharmaceutical and biotechnology companies for specialized knowledge in early drug development phases. It offers the sponsors access to process development, analytical knowledge, formulation expertise, and technical resources while helping sponsors to streamline the timeline of the development process and save internal costs. More emerging biotechnology companies and increasingly complex drug candidates in the market have increased the demand for development partners. CDMOs are also increasingly improving their integrated development platform to provide complete development services from early discovery to clinical development phase.

By Development Phase, Commercial Dominates and Phase I Grows Fastest

Commercial operations take the lead in the Healthcare CDMO market in 2025 because there will be an increase in the need for outsourced manufacturing services as pharmaceutical products enter the stage of manufacture and supply. Commercial initiatives are characterized by the need for capacity, validation, compliance, quality control, and reliable execution of logistics services. Pharmaceutical companies are looking to outsource commercial activities to help them with large-scale manufacturing without losing portfolio flexibility. The rising use of generics, specialty pharmaceuticals, and conventional medicines fuels commercial outsourcing. CDMOs will have to invest in scalability of manufacturing operations to cater to continuous production activities.

Phase I is the segment that will experience the most rapid growth throughout the forecast period due to the growing pipelines of pharmaceutical and biotechnology companies and the increased collaborations of sponsors with third parties in clinical phase. Outsourcing clinical research activities helps sponsors get manufacturing, analytical, formulation, and regulatory expertise required to progress their drug candidates. Increased involvement of emerging biotechnology and virtual organizations is increasing demand for outsourcing solutions in early clinical development. CDMOs will have to strengthen their Phase I capabilities to serve clinical supply demands of their clients.

By Therapeutic Area, Oncology Dominates and Neurology Grows Fastest

Oncology segment dominates the Healthcare CDMO market in 2025 because of the scale and complexities involved in developing and manufacturing drugs for cancer treatment. More companies from the pharmaceutical and biotechnology industries are partnering with CDMOs to develop oncology products due to the need for unique capabilities involving potent active ingredients, complex formulations, biologics, and advanced manufacturing technologies. With the increased development of targeted medicines and precision treatments, the need to have such expertise is growing. There are efforts by CDMOs to increase their capacities concerning containment, analysis, and manufacturing of oncology products, hence ensuring outsourcing in clinical and commercial phases.

Neurology is the segment that will witness the highest growth rate over the forecast period due to more pipelines being developed targeting neurodegenerative diseases and other disorders within the central nervous system. Such medicines usually require special attention during development due to complex formulation, manufacture, and regulation. It is therefore necessary for the sponsors to partner with external entities with experience in this field. Due to increased focus on neurology research, along with increased pharmaceutical outsourcing, there are more possibilities for CDMOs operating in this space.

By End-User, Big Pharmaceutical Companies Dominate and Emerging & Virtual Biotech Firms Grow Fastest

Big Pharmaceutical Companies will remain the dominant players within the Healthcare CDMO market during 2025 due to the significant outsourcing requirements that these companies have regarding their drug development, manufacturing, packaging, and regulatory affairs processes. Big pharmaceuticals are increasingly turning to CDMOs as a means to extend their internal capacity, get access to particular technologies, and improve overall business flexibility. In addition, outsourcing allows these companies to handle the complexity of their product portfolio in different stages of development and commercialization, which is accompanied by the constant demand for small molecules, biologics, specialties, and generic drugs.

Emerging and Virtual Biotech Companies will be the fastest-growing segments throughout the forecast period because of the higher level of dependence on the third-party providers of development and manufacturing services as a result of the light-asset strategy that they follow. Limited internal capacity forces these companies to collaborate with CDMOs to conduct process development, analytical testing, clinical manufacturing, regulatory affairs, and commercialization processes. Expanding pipeline of biotechnology and investments into the innovative therapeutic modalities increase the number of potential customers of CDMOs.

Regional Analysis

North America Healthcare CDMO Market Insights

North America accounted for approximately 42.10% of the global Healthcare CDMO Market in 2025, the largest share of any region, anchored by deep FDA familiarity, established cold-chain logistics, and a concentration of sponsor headquarters and innovation hubs. The United States drives the substantial majority of regional demand, supported by strong outsourcing demand for biologics, cell and gene therapies, and sterile injectables from a dense population of pharmaceutical and biotechnology companies.

Canada and Mexico contribute a smaller but steadily growing share of regional revenue as investments in modern facilities, automation, and advanced bioprocessing improve operational capabilities. Compliance with Health Canada standards and proximity to the U.S. market continue to make Canadian CDMOs appealing partners for efficient, high-quality contract development and manufacturing solutions.

Europe Healthcare CDMO Market Insights

Europe enjoys an enviable position in the global marketplace by combining a demanding culture of quality with a beneficial research and development tax regime. Within Europe, Germany, the UK, and France are the key contributors at the national level. The manufacture of high-value biologics takes place in Switzerland, Ireland, and Germany, whereas cost-competitive capabilities for oral dosing and sterilized packaging can be found in Eastern Europe.

Germany enjoys the largest national market share in Europe because of the strong presence of pharmaceutical manufacturing facilities, research and development environment, and the manufacturing of high-value biologics and biosimilars. The UK is expanding its capabilities in cell and gene therapy and personalized medicine because of collaborations with major pharmaceutical companies worldwide and through the MHRA regulations.

Asia Pacific Healthcare CDMO Market Insights

Asia Pacific emerges as the fastest growing regional market, with a projected CAGR of 11.60% between 2026 and 2035. Scale-up grants and government subsidies are responsible for reducing capital costs of GMP suites in China, Singapore, and South Korea. China accounts for the largest national market in the region on account of favorable government policies, increased biologic drug manufacturing, and high pharmaceutical outsourcing.

India is developing quickly on account of low-cost production, sound generic drugs production, and increasing demand for biological drugs. Domestic CDMO players have started to shift towards complex drugs and biosimilars along with improved regulatory compliance to match FDA, EMA, and WHO guidelines. Japan and South Korea maintain their position as technology-savvy markets providing high-end services like sterile injectables and precision medicines based on regulatory compliance with PMDA and national quality standards.

MEA & Latin America Healthcare CDMO Market Insights

There is immense potential for sustained growth within the Middle East and Africa region as there will be greater demand for affordable medicines, increased investment in healthcare by governments, and increased clinical research activities. There has been an expansion of CDMO operations in terms of generic drugs and sterile products as well as collaboration with multinational companies in the region, especially in the United Arab Emirates.

Latin America has made tremendous progress due to the increased outsourcing of pharmaceuticals, government healthcare programs, and rising demand for affordable medicines in the region. Brazil and Argentina have shown tremendous progress within Latin America as there have been expansions in manufacturing capacity and connections with multinational companies. The CDMOs within Brazil have enhanced their manufacturing capability in generics, biologics, and sterile products despite the challenges in supply chain and economic stability.

Market Dynamics

Growth Drivers: Rising Outsourcing of Complex Biologics and Advanced Therapies

Growth in the Healthcare CDMO Market is fundamentally supported by the rapid expansion of biologics, biosimilars, cell and gene therapies, antibody-drug conjugates, mRNA platforms, and personalized medicines, products that require highly specialized manufacturing infrastructure and sophisticated analytical capabilities. An estimated 86.9% of drug originators now outsource at least one manufacturing activity, as portfolio simplification enables sponsors to redeploy capital toward discovery while transferring fixed-asset risk to capable outsourcing partners.

The increase in molecular complexity in particular for combination products such as ADCs that combine the biologic and chemical supply chains in one release specification is elevating the importance of vertical integration among CDMOs. AI-enabled process optimization is fueling expansion through the rapid scale-up of technology transfer, while diversification of the supply chain is creating new opportunities for outsourcing, in particular in the Asia-Pacific region.

Restraints: Regulatory Complexity and Capacity Constraints

The challenge of regulatory complexity continues to be one of the major barriers for healthcare CDMOs. Manufacturers should keep up with changes imposed by FDA, EMA, PMDA, and many other global regulatory bodies. This requires significant expenditure for the quality management system, documentation, validation procedures, and training of personnel. In 2024-2025, an increase in warning letters related to issues with sterile process controls and data integrity was observed; the cost of rectification in this case amounted to roughly $14.8 million per each violation without the cost of revenue losses due to supply disruptions.

On top of that, shortages in capacity and long lead time for CDMOs persist in the market despite the numerous expansions of capacities. Allocation periods for specialized suites used in production of antibody-drug conjugates take 24-36 months on average. Even the new facilities announced by key players will be opened no sooner than in 2028. In such a way, the negotiating power of integrated CDMOs will only increase further.

Opportunities: AI-Driven Process Optimization and Emerging Modality Manufacturing

Integrating AI in technology transfer processes and process control represents a huge opportunity. Predictive analytics along with digital twin technologies can help reduce the scale-up cycles up to 30% while simultaneously cutting material usage and unplanned downtime. Players offering the right mix of regulatory expertise across the globe, flexible capacities and technological platforms will be able to claim the market leadership, as sponsors are more and more interested in comprehensive solutions.

White-space future opportunities would comprise personalized vaccine manufacturing, manufacturing of CRISPR gene editing solutions and combination devices-drugs manufacturing due to current limited capacity compared to sponsors’ pipelines' growth. Regulatory solutions enabling quicker review of advanced manufacturing platforms can enable quick players to catch up with the incumbent scale if they are able to show compliance readiness, whereas expansion into new emerging regions like Asia-Pacific and Latin America provides a big enough runway for established companies.

Recent Developments:

• 2025: Jabil acquired Pharmaceutics International, Inc. (Pii), expanding pharmaceutical capabilities and enabling end-to-end drug development support, including advanced delivery systems and commercial-scale manufacturing.

• 2025: Agilent Technologies completed its approximately USD 925 million acquisition of BIOVECTRA, strengthening North American viral-vector manufacturing capabilities and advanced therapy supply-chain operations.

• 2025: Samsung Biologics added 360,000 liters of manufacturing capacity across Plants 4 and 5 and secured a USD 1.4 billion multi-product manufacturing deal.

• 2026: Catalent and Nanoscope Therapeutics expanded their partnership for MCO-010, supporting late-phase development, commercial supply, and packaging validation for gene therapy commercialization programs.

• 2026: Lonza expanded payload-linker manufacturing capacity at its Visp, Switzerland site to meet growing antibody-drug conjugate demand, with new operations expected online in 2028.

Healthcare CDMO Market Key Players

• Catalent, Inc.

• Lonza Group AG

• Thermo Fisher Scientific, Inc.

• Samsung Biologics Co., Ltd.

• WuXi AppTec Co., Ltd.

• Recipharm AB

• Siegfried Holding AG

• Labcorp Drug Development

• Jabil Inc.

• Syngene International Limited

• IQVIA Inc.

• Almac Group

• Ajinomoto Bio-Pharma Services

• Alcami Corporation

• Vetter Pharma International GmbH

• FUJIFILM Holdings Corporation

• Baxter International Inc.

• Cambrex Corporation

• PCI Pharma Services

• Piramal Pharma Limited

Healthcare CDMO Market Report Scope: